Clinical Trial Update: Escitalopram for Agitation in Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating escitalopram for agitation in Alzheimer's disease is ongoing. The study status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Lexapro (escitalopram)

Snippet

Sponsor: JHSPH Center for Clinical Trials | Conditions: Dementia | Phase 3 | Status: ACTIVE_NOT_RECRUITING